IN2014CN04071A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN04071A IN2014CN04071A IN4071CHN2014A IN2014CN04071A IN 2014CN04071 A IN2014CN04071 A IN 2014CN04071A IN 4071CHN2014 A IN4071CHN2014 A IN 4071CHN2014A IN 2014CN04071 A IN2014CN04071 A IN 2014CN04071A
- Authority
- IN
- India
- Prior art keywords
- antigen
- tcdb
- relates
- tcda
- difficile
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201121149A GB201121149D0 (en) | 2011-12-08 | 2011-12-08 | Clostridium difficile toxin-based vaccine |
GBGB1217321.7A GB201217321D0 (en) | 2012-09-27 | 2012-09-27 | Vaccine |
PCT/IB2012/002955 WO2013084071A2 (en) | 2011-12-08 | 2012-12-07 | Clostridium difficile toxin-based vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN04071A true IN2014CN04071A (ja) | 2015-10-23 |
Family
ID=47747684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN4071CHN2014 IN2014CN04071A (ja) | 2011-12-08 | 2012-12-07 |
Country Status (15)
Country | Link |
---|---|
US (1) | US9694063B2 (ja) |
EP (1) | EP2788022B1 (ja) |
JP (1) | JP6084631B2 (ja) |
KR (1) | KR20140101835A (ja) |
CN (1) | CN103974718A (ja) |
AU (1) | AU2012349753A1 (ja) |
BR (1) | BR112014013876A2 (ja) |
CA (1) | CA2858519A1 (ja) |
ES (1) | ES2704069T3 (ja) |
IL (1) | IL232957A0 (ja) |
IN (1) | IN2014CN04071A (ja) |
MX (1) | MX2014006630A (ja) |
RU (1) | RU2014127714A (ja) |
SG (1) | SG11201402375VA (ja) |
WO (1) | WO2013084071A2 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2592686C2 (ru) | 2011-04-22 | 2016-07-27 | ВАЙЕТ ЭлЭлСи | Композиции, относящиеся к мутантному токсину clostridium difficile, и способы их применения |
SG11201500980WA (en) | 2012-09-19 | 2015-04-29 | Novartis Ag | Clostridium difficile polypeptides as vaccine |
BR122016023101B1 (pt) * | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
WO2014197651A1 (en) * | 2013-06-05 | 2014-12-11 | Tufts University | Atoxic recombinant holotoxins of clostridium difficile as immunogens |
KR102395498B1 (ko) | 2014-01-06 | 2022-05-09 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용 |
CN106536544B (zh) * | 2014-06-25 | 2020-04-07 | 葛兰素史密丝克莱恩生物有限公司 | 艰难梭菌免疫原性组合物 |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US10668140B2 (en) | 2017-02-24 | 2020-06-02 | University Of South Floirida | Non-toxigenic Clostridium difficile spores for use in oral vaccination |
US10555992B2 (en) | 2017-05-31 | 2020-02-11 | University Of South Florida | Immunogenic proteins against clostridium difficile |
US10933126B2 (en) | 2018-05-03 | 2021-03-02 | The Board Of Regents Of The University Of Oklahoma | Clostridium difficile immunogenic compositions and methods of use |
WO2020237090A1 (en) * | 2019-05-21 | 2020-11-26 | The Regents Of The University Of California | Vaccine compositions for clostridium difficile |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
AU627226B2 (en) | 1988-08-25 | 1992-08-20 | Liposome Company, Inc., The | Influenza vaccine and novel adjuvants |
DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
CA2006700A1 (en) | 1989-01-17 | 1990-07-17 | Antonello Pessi | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
AU651949B2 (en) | 1989-07-14 | 1994-08-11 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
GB2276169A (en) | 1990-07-05 | 1994-09-21 | Celltech Ltd | Antibodies specific for carcinoembryonic antigen |
IL98715A0 (en) | 1990-08-13 | 1992-07-15 | American Cyanamid Co | Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
PL170980B1 (pl) | 1992-06-25 | 1997-02-28 | Smithkline Beecham Biolog | Szczepionka PL PL PL PL PL PL PL |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
NZ295998A (en) * | 1994-10-24 | 1999-10-28 | Ophidian Pharm Inc | Neutralizing antitoxins against clostridium difficile and clostidium botulinum toxins |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
NZ312502A (en) | 1995-07-07 | 1999-03-29 | Oravax Inc | Clostridium difficile toxins as mucosal adjuvants |
US5707829A (en) | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
WO1998008540A1 (en) | 1996-08-28 | 1998-03-05 | Ophidian Pharmaceuticals, Inc. | Multivalent vaccine for clostridium botulinum neurotoxin |
DK1005368T3 (da) | 1997-03-10 | 2010-01-04 | Ottawa Hospital Res Inst | Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
AU746859B2 (en) | 1997-06-20 | 2002-05-02 | Imperial College Of Science, Technology And Medicine | Immonogenic fragments of toxin a of clostridium difficile |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
ES2298316T3 (es) | 1997-09-05 | 2008-05-16 | Glaxosmithkline Biologicals S.A. | Emulsiones de aceite en agua que contienen saponinas. |
GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
AU759391B2 (en) | 1998-02-12 | 2003-04-10 | Wyeth Holdings Corporation | Pneumococcal and meningococcal vaccines formulated with interleukin-12 |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
WO1999052549A1 (en) | 1998-04-09 | 1999-10-21 | Smithkline Beecham Biologicals S.A. | Adjuvant compositions |
US20020009429A1 (en) * | 1999-01-29 | 2002-01-24 | Galagen, Inc. | Pharmaceutical composition comprising a selected antigen and candida species antigen and methods |
MY125202A (en) | 1999-03-19 | 2006-07-31 | Smithkline Beecham Biologicals S A | Vaccine |
JP2002541808A (ja) | 1999-04-09 | 2002-12-10 | テクラブ, インコーポレイテッド | ポリサッカリド結合体ワクチンのための組換えトキシンaタンパク質キャリア |
JP2002542169A (ja) | 1999-04-09 | 2002-12-10 | テクラブ, インコーポレイテッド | Clostridiumdifficileに対する、組換え毒素A/毒素Bワクチン |
US6733760B1 (en) * | 1999-04-09 | 2004-05-11 | Techlab, Inc. | Recombinant toxin A/toxin B vaccine against Clostridium difficile |
GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
AU2001258107A1 (en) * | 2000-05-10 | 2001-11-20 | Glycodesign Inc. | Designing modulators for glycosyltransferases |
MXPA03003690A (es) | 2000-10-27 | 2004-05-05 | Chiron Spa | Acidos nucleicos y proteinas de los grupos a y b de estreptococos. |
AU2002338233A1 (en) * | 2001-03-30 | 2002-10-15 | Basf Plant Science Gmbh | Glucan chain length domains |
EP1450856B1 (en) | 2001-09-14 | 2009-11-11 | Cytos Biotechnology AG | Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use |
AU2002347404A1 (en) | 2001-09-14 | 2003-04-01 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
US7226597B2 (en) | 2002-06-17 | 2007-06-05 | The Board Of Regents Of The University Of Oklahoma | Mutants of Clostridium difficile toxin B and methods of use |
US20040235139A1 (en) * | 2002-12-23 | 2004-11-25 | Demain Arnold L. | Clostridium difficile culture and toxin production methods |
HUE024962T2 (en) | 2004-02-06 | 2016-02-29 | Univ Massachusetts | Antibodies to Clostridium difficile toxins and their uses |
WO2006071877A2 (en) | 2004-12-27 | 2006-07-06 | Progenics Pharmaceuticals (Nevada), Inc. | Orally deliverable and anti-toxin antibodies and methods for making and using them |
US20060228369A1 (en) | 2005-04-11 | 2006-10-12 | Program For Appropriate Technology In Health | Stabilization and preservation of temperature-sensitive vaccines |
US8852600B2 (en) | 2006-06-08 | 2014-10-07 | The Rockefeller University | Codon-optimized DNA molecules encoding the receptor binding domains of Clostridium difficile toxins A and B, and methods of use thereof |
EP2054044B1 (de) | 2006-08-02 | 2014-07-23 | Johannes Gutenberg-Universität Mainz | Arzneimittel gegen lct-vergiftungen |
EP2167119B1 (en) | 2007-06-14 | 2016-08-24 | The Secretary of State for Health | Chemically modified peptides with improved immunogenicity |
WO2008156676A1 (en) * | 2007-06-15 | 2008-12-24 | President And Fellows Of Harvard College | Methods and compositions for detecting and modulating o-glycosylation |
US20120020996A1 (en) | 2008-08-06 | 2012-01-26 | Jonathan Lewis Telfer | Vaccines against clostridium difficile and methods of use |
WO2010094970A1 (en) | 2009-02-20 | 2010-08-26 | Health Protection Agency | Antibodies to clostridium difficile toxins |
CN102612562A (zh) | 2009-08-27 | 2012-07-25 | 色奈普提科研究有限公司 | 一种新的用于生成诱导性多能干(iPS)细胞或组织特异性细胞的蛋白质递送系统 |
US10046040B2 (en) | 2009-11-16 | 2018-08-14 | University Of Maryland, Baltimore | Multivalent live vector vaccine against Clostridium difficile-associated disease |
US20120282274A1 (en) | 2009-11-20 | 2012-11-08 | Northshore University Health System Research Institute | Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment |
CA2782406A1 (en) * | 2009-12-02 | 2011-06-09 | Tufts University | Atoxic recombinant holotoxins of clostridium difficile as immunogens |
GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
AU2011238711B2 (en) | 2010-03-30 | 2015-06-18 | Pelican Technology Holdings, Inc. | High level expression of recombinant toxin proteins |
MX339253B (es) * | 2010-04-15 | 2016-05-18 | Progenics Pharm Inc | Anticuerpos para el tratamiento de infeccion y enfermedad asociadas con clostridium dificile. |
ES2867375T3 (es) | 2010-09-03 | 2021-10-20 | Valneva Austria Gmbh | Polipéptido aislado de las proteínas de la toxina A y la toxina B de C. difficile y sus usos |
US8431361B2 (en) | 2010-09-17 | 2013-04-30 | Board Of Regents Of The University Of Oklahoma | Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B |
GB201016742D0 (en) * | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
WO2012118693A1 (en) | 2011-02-28 | 2012-09-07 | Northshore University Healthsystem | Methods of diagnosing clostridium difficile infection |
RU2592686C2 (ru) * | 2011-04-22 | 2016-07-27 | ВАЙЕТ ЭлЭлСи | Композиции, относящиеся к мутантному токсину clostridium difficile, и способы их применения |
US9409974B2 (en) | 2011-05-27 | 2016-08-09 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
AR087716A1 (es) * | 2011-08-31 | 2014-04-09 | Valent Biosciences Corp | Composiciones reguladoras del crecimiento de plantas, metodos de preparacion y usos de las mismas |
AR089797A1 (es) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
GB201223342D0 (en) * | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
-
2012
- 2012-12-07 AU AU2012349753A patent/AU2012349753A1/en not_active Abandoned
- 2012-12-07 IN IN4071CHN2014 patent/IN2014CN04071A/en unknown
- 2012-12-07 US US14/363,387 patent/US9694063B2/en active Active
- 2012-12-07 CN CN201280060487.1A patent/CN103974718A/zh active Pending
- 2012-12-07 KR KR1020147018480A patent/KR20140101835A/ko not_active Application Discontinuation
- 2012-12-07 RU RU2014127714A patent/RU2014127714A/ru not_active Application Discontinuation
- 2012-12-07 BR BR112014013876A patent/BR112014013876A2/pt not_active IP Right Cessation
- 2012-12-07 ES ES12826538T patent/ES2704069T3/es active Active
- 2012-12-07 MX MX2014006630A patent/MX2014006630A/es unknown
- 2012-12-07 EP EP12826538.6A patent/EP2788022B1/en active Active
- 2012-12-07 SG SG11201402375VA patent/SG11201402375VA/en unknown
- 2012-12-07 WO PCT/IB2012/002955 patent/WO2013084071A2/en active Application Filing
- 2012-12-07 CA CA2858519A patent/CA2858519A1/en not_active Abandoned
- 2012-12-07 JP JP2014545387A patent/JP6084631B2/ja active Active
-
2014
- 2014-06-05 IL IL232957A patent/IL232957A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112014013876A2 (pt) | 2019-09-24 |
WO2013084071A2 (en) | 2013-06-13 |
CN103974718A (zh) | 2014-08-06 |
ES2704069T3 (es) | 2019-03-14 |
MX2014006630A (es) | 2014-07-09 |
RU2014127714A (ru) | 2016-01-27 |
EP2788022B1 (en) | 2018-10-31 |
WO2013084071A3 (en) | 2013-11-07 |
US20150132333A1 (en) | 2015-05-14 |
US9694063B2 (en) | 2017-07-04 |
AU2012349753A1 (en) | 2014-06-19 |
SG11201402375VA (en) | 2014-10-30 |
JP2015500827A (ja) | 2015-01-08 |
KR20140101835A (ko) | 2014-08-20 |
CA2858519A1 (en) | 2013-06-13 |
JP6084631B2 (ja) | 2017-02-22 |
IL232957A0 (en) | 2014-07-31 |
EP2788022A2 (en) | 2014-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN04071A (ja) | ||
MX342240B (es) | Anticuerpos anti-fgfr4 y metodos de uso. | |
TN2015000050A1 (en) | Methods of treating a tauopathy | |
NZ715815A (en) | High-stability t-cell receptor and preparation method and application thereof | |
MX352324B (es) | Vacunas multivalentes de nanovehiculos sinteticos. | |
PH12014501427B1 (en) | Anti-phf-tau antibodies and their uses | |
MX2014004022A (es) | Anticuerpos anti-htra1 y metodos de uso. | |
MX2013015311A (es) | Polipeptidos de enlace de pcsk9 y metodos de uso. | |
CR20150046A (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
MX2014002053A (es) | Anticuerpos anti -mcsp y metodos de uso. | |
HUE040211T2 (hu) | Mikrobióta-helyreállítási terápia (MRT), készítmények és elõállítási eljárások | |
IN2014DN05885A (ja) | ||
TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
MX2013001473A (es) | Anticuerpos contra il-18r1 y usos de los mismos. | |
AU337887S (en) | Allsaw | |
AU2013225816A8 (en) | Compositions and methods for treating Type III Gaucher Disease | |
EP4023243A3 (en) | Compositions and methods for treating celiac sprue disease | |
MX357675B (es) | Anticuerpos anti-jagged y métodos de uso. | |
WO2013123046A3 (en) | Cathode buffer materials and related devices and methods | |
PH12015501854A1 (en) | Factor ix polypeptide formulations | |
UA112760C2 (uk) | Теобромін у комбінації з гвайфенезином для лікування кашлю | |
MX2023003000A (es) | Formulaciones de liberacion modificada de viloxacina. | |
IN2015DN00820A (ja) | ||
AU337888S (en) | Allsaw | |
MX2016009665A (es) | Composiciones y metodos para el tratamiento de la hemorragia cerebral. |